The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Dubash, S, Bridgewood, C, McGonagle, D et al. (1 more author) (2019) The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Review of Clinical Immunology, 15 (2). pp. 123-134. ISSN 1744-666X

Abstract

Metadata

Authors/Creators:
  • Dubash, S
  • Bridgewood, C
  • McGonagle, D
  • Marzo-Ortega, H
Copyright, Publisher and Additional Information: This is an author produced version of a paper published in Expert Review of Clinical Immunology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Interleukin-17 inhibitors, IL-17 inhibition, IL-17A blockers, ankylosing spondylitis, axial spondyloarthritis, axSpA, secukinumab, ixekizumab, brodalumab
Dates:
  • Accepted: 17 December 2018
  • Published (online): 21 December 2018
  • Published: 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Jan 2019 14:31
Last Modified: 21 Dec 2019 01:39
Status: Published
Publisher: Taylor & Francis
Identification Number: https://doi.org/10.1080/1744666x.2019.1561281
Related URLs:

Share / Export

Statistics